Provincial squeeze on generic prices continues

Moulton, donalee
October 2011
CMAJ: Canadian Medical Association Journal;10/4/2011, Vol. 183 Issue 14, pE1049
Academic Journal
The article reports on the development of Fair Drug Pricing Act, a pharmacare program in Nova Scotia. It highlights the nationwide trend in clamping down the generic prices of drugs that has started in Ontario. It adds that under the pharmacare program of Nova Scotia, only 45% of the cost of a brand drug for an equivalent generic will be paid. The hope of the province to generate millions from their pharmaceutical shopping bill by reducing the generic drug prices is also emphasized.


Related Articles

  • BUZZ 'N BYTES.  // Drug Store News;10/20/2014, Vol. 36 Issue 10, p46 

    The article offers news briefs in the pharmaceutical sector in the U.S. as of late October 2014, namely, the report by the Generic Pharmaceutical Association showing that generic drugs saved the U.S. health system 239 billion dollars in 2013 and the 30th anniversary celebration of the Drug Price...

  • Pharmaceutical Policy regarding Generic Drugs in Belgium. Simoens, Steven; De Bruyn, Kristien; Bogaert, Marc; Laekeman, Gert // PharmacoEconomics;2005, Vol. 23 Issue 8, p755 

    Pressure to control pharmaceutical expenditure and price competition among pharmaceutical companies are fuelling the development of generic drug markets in EU countries. However, in Belgium, the market for generic drugs is underdeveloped compared with other countries. To promote the use of...

  • Generic Makers Look to Branding. Ruth, João-Pierre S. // njbiz;7/26/2004, Vol. 17 Issue 30, p25 

    Focuses on the generic drug business of pharmaceutical companies in the U.S. Approval sought by pharmaceutical companies to the U.S. Food and Drug Administration to sell their generic drugs; Remarks from Chris Eso, senior investor relations specialist of Watson Pharmaceuticals, on the sales of...

  • Just roiling along. Tieman, Jeff; Hallam, Kristen // Modern Healthcare;10/23/2000, Vol. 30 Issue 44, p8 

    Reports the reactions of pharmaceutical companies to the regulation of prescription drug prices in Maine. Reasons of pharmaceutical companies for contesting the law; Information on the lawsuit filed by the Pharmaceutical Research and Manufacturers of America.

  • Prescription Drug Brouhaha. Adrianson, Alex W. // Consumers' Research Magazine;Sep2000, Vol. 83 Issue 9, p38 

    Focuses on the reaction of the pharmaceutical industry to the proposed law on drug prices in Maine. Lawsuit filed by the Pharmaceutical Research and Manufacturers of America; Overview of the law.

  • Reforming Spain's pharmaceutical industry. Ruiz, Magdalena // BMJ: British Medical Journal (International Edition);5/6/89, Vol. 298 Issue 6682, p1206 

    Focuses on the reforms in the pharmaceutical industry in Spain. Introduction of a bill for the substitution of a prescribed drug with another with the same composition; Regulation of the production, quality control, distribution of drugs and pricing of drugs; Objectives of the bill.

  • Health care purchasing at risk. Betz, Robert // Health Systems Review;Jan/Feb95, Vol. 28 Issue 1, p21 

    Comments on marketplace and government pressures on pharmaceutical pricing. Effects of prescription drug discounts on consumers, health care providers and insurers; Implications of Section 1555 of the Federal Acquisition Streamlining Act of 1994; Regulation of access to the General Services...

  • AIDS Drugs & the Pharmaceutical Industry: A Need For Reform. Griffin, Mary T. // American Journal of Law & Medicine;1991, Vol. 17 Issue 4, p363 

    The pharmaceutical industry has long enjoyed substantial profits despite increased requirements for drug approval and various attempts to regulate the industry. Drug companies have avoided effective regulation by blaming high prices on the costs of research and development. The search for drugs...

  • Bl and Lilly's Trajenta battle.  // Pharmaceutical Executive;Nov2011, Vol. 31 Issue 11, p36 

    The article discusses the impact of the German pharmaceutical pricing reform program, Arzneimittelmarktneuordnungsgesetz (AMNOG), on new drugs, that motivated pharmaceutical firm Bl and Lilly to decide not to launch the Trajenta drug in Germany.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics